Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells

Journal of Endocrinology

Volumn 155, Issue 3, 1997, Pages 491-500

  Corrales, J J ^a   Lopez A ^b   Ciudad, J ^b   Mories, M T ^a   Miralles, J M ^a   Orfao, A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; THIAMAZOLE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; REMISSION; T LYMPHOCYTE ACTIVATION;

EID: 1842293991     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1550491     Document Type: Article

References (46)

1. Abbas AK, Lichtman AH & Pober JS 1994 Cellular and Molecular Immunology. Philadelphia: W.B. Saunders Co.
2. Aust G, Lehman Y & Heberling HJ 1996 Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease. Experimental and Clinical Endocrinology and Diabetes 104 50-58.
3. Brieva JA, Targan S & Stevens RH 1984 NK and T cell subsets regulate antibody production by human in vivo antigen-induced lymphoblastoid B cells. Journal of Immunology 132 611-615.
4. Chan JYC & Walfish PG 1986 Activated (Ia+) T-lymphocytes and their subsets in autoimmune thyroid diseases: analysis by dual laser flow microfluorocytometry. Journal of Clinical Endocrinology and Metabolism 62 403-409.
5. Corrales JJ, Tabernero JM, Miralles JM & Hernández MT 1991 Effects of subclinical hyperthyroidism on renal handling of water and electrolytes in patients with nodular goiter. Klinische Wochenschrift 69 19-24.
6. Corrales JJ, Orfao A, Miralles JM & San Miguel J 1994 The relationship between hyperthyroidism and the distribution of peripheral blood T, NK and B-lymphocytes in multinodular goiter. Hormone and Metabolic Research 26 104-108.
7. Corrales JJ, Orfao A, López A, Mories MT, Miralles JM & Ciudad J 1996a CD5+ B cells in Graves' disease: correlation with disease activity. Hormone and Metabolic Research 28 280-285.
8. Corrales JJ, Orfao A, López A, Ciudad J & Mories MT 1996b Serial analysis of the effects of methimazole therapy on circulating B cells subsets in Graves' disease. Journal of Endocrinology 151 231-240.
9. Eguchi K, Ueki Y, Shimomura, Otsubo T, Nakao H, Migita K, Kawakami A, Matsunaga M, Tezuka H, Ishikawa N, Ito K & Nagataki S 1989 Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. Journal of Immunology 142 4233-4240.
10. Eisenstein Z, Engelsman E, Weiss M, Kalechman Y & Sredni B 1994 Modulation of the IL-2 production defect in vitro in Graves' disease. Clinical and Experimental Immunology 96 323-328.
11. Engler H, Taurog A, Luthy C & Dorris ML 1983 Reversible and irreversible inhibition of thyroid peroxidase-catalysed iodination by thioureylene drugs. Endocrinology 112 86-95.
12. Fan JL, Desai RK, Dallas JS, Wagle NM, Seetharamaiah GS & Prabhakar BS 1994 High frequency of B cells capable of producing anti-thyrotropin receptor antibodies in patients with Graves' disease. Clinical Immunology and Immunopathology 71 69-74.
13. Hara T, Jung LKL, Bjorndahl JM & Fu SM 1986 Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA-1) by 12-o-tetraconoyl phorbol-13-acetate, mitogens, and antigens. Journal of Experimental Medicine 164 1988-2005.
14. Iwatani Y, Amino N, Kabutomori O, Mon H, Tamaki H, Motoi S, Izumiguchi Y & Miyai K 1984 Decrease in peripheral large granular lymphocytes in Graves' disease. Clinical and Experimental Immunology 55 239-244.
15. Iwatani Y, Amino N, Hidaka Y, Kaneda T, Ichihara K, Tamaki H, Matsuzuka F, Fukata S, Kuma K & Miyai K 1992 Decreases in αβ T cell receptor negative T cells and CD8 cells, and an increase in CD4+CD8+ cells in active Hashimoto's disease and subacute thyroiditis. Clinical and Experimental Immunology 87 444-449.
16. lo/-CD4 - CD8 - cells, in autoimmune thyroid disease. Clinical and Experimental Immunology 93 430-436.
17. Karlsson FA & Tötterman TH 1988 Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells. Clinical and Experimental Immunology 74 258-263.
18. Kishimoto T, Akira S & Taga T 1992 Interleukin-6 and its receptor: a paradigm for cytokines. Science 258 593-597.
19. Koukkou E, Panayiotidis P, Alevizou-Terzaki V & Thalassinos N 1991 High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independency from the etiology of the hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 73 771-776.
20. López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P & Sánchez-Madrid F 1993 Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamilly ot signal transmitting receptors. Journal of Experimental Medicine 178 537-547.
21. Ludgate ME, McGregor AM, Weetman AP, Ratanachaiyaivong S, Lazarus JH, Hall R & Middleton GW 1984 Analysis of T cell subsets in Graves' disease: alterations associated with carbimazole. British Medical Journal 288 526-530.
22. Luo W, Van de Velde H, Von Hoegen Y, Parnes JR & Thielemans K 1992 Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72). Journal of Immunoloay 148 1630-1634.
23. McIntosh RS, Tandon N, Pickerill AP, Davies R, Barnett D, Weetman AP 1993 IL-2 receptor-positive intrathyroidal lymphocytes in Graves' disease. Analysis of Vα transcript microheterogeneity. Journal of Immunology 151 3884-3893.
24. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, Augugliaro R, Bottino C, Ciccone E & Moretta L 1991 CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lypmhoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor α/β. Journal of Experimental Medicine 174 1393-1398.
25. Mories MT, Miralles JM, Reglero A, Felipe S, Corrales JJ & García LC 1991 A study of the thyroglobulin and perxoidase activity in the thyroid tissue of patients with non-endemic non-toxic nodular goiter. Clinical Science 80 301-307.
26. Nabel G, Allard WJ & Cantor H 1982 A cloned cell line mediating natural killer cell function inhibits immunoglobulin secretion. Journal of Experimental Medicine 156 658-663.
27. Nakamura S, Sung SSJ, Bjorndahl JM & Fu SM 1989 Human T cell activation. IV. T cell activation and proliferation via the early activation antigen EA 1. Journal of Experimental Medicine 169 677-689.
28. Nitta T, Yagita H, Sato K & Okumura K 1989 Involvement of CD56 (NKH-1/Leu 19 antigen) as an adhesion molecule in natural killer-target cell interaction. Journal of Experimental Medicine 170 1757-1761.
29. Patel SS, Wacholtz MC, Duby AD, Thiele DL & Lipsky PE 1989 Analysis of the functional capabilities of CD3+CD4 - CD8 - and GD3+GD4+CD8+ human T cell clones. Journal of Immunology 143 1108-1117.
30. Ratanachaiyavong S & McGregor AM 1985 Immunosuppressive effects of antithyroid drugs. Clinics in Endocrinology and Metabolism 14 449-466.
31. Smith KA 1988 Interleukin-2: inception, impact, and implications. Science 240 1169-1176.
32. Soliman M, Kaplan E, Abdel-Latif A, Scherberg N & DeGrcoot LJ 1995 Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases? Journal of Clinical Endocrinology and Metabolism 80 2312-2321.
33. Stanton T, Stevens TL, Ledhetter JA & Wofsy D 1986 Anti-Ly-1 antibody induces interleukin 2 release from T cells. Journal of Immunology 136 1734-1738.
34. Stockinger H, Majdic O & Knapp W 1995 1995 directory for the human leukocyte clusters of differentiation. Transfusion 36 268-285.
35. Taniguchi T & Minami Y 1993 The IL-2/IL-2 receptor system: a current overview. Cell 73 5-8.
36. Testi R, Phillips JH & Lanier LL 1989a Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. Requirement for receptor cross-linking, prolonged elevation of intracellular (Ca++) and stimulation of protein kinase C. Journal of Immunology 142 1854-1860.
37. Testi R, Phillips JH & Lanier LL 1989b T cell activation via Leu 23 (CD69). Journal of Immunology 143 1123-1128.
38. Tötterman TH, Karlsson FA, Bengtsson M & Mendel-Hartvig Y 1987 Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. New England Journal of Medicine 316 15-22.
39. Volpé R 1994 Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte - immunocyte signaling: a review. Thyroid 4 217-223.
40. Walfish PG & Tseng KH 1992 Intrathyroidal activated (Ia+) T-lymphocyte CD+ subsets and B cells in Graves' hyperthyroidism respond rapidly to propylthiouracil therapy: demonstration using fine needle aspirates and two-colour laser flow cytometry. Autoimmunity 13 35-11.
41. Wall J 1995 Extrathyroidal manifestations of Graves' disease. Journal of Clinical Endocrinology and Metabolism 80 3427-3429.
42. Wang PW, Luo SF, Huang BY, Lin JD & Huang MJ 1988 Depressed natural killer activity in Graves' disease and during antithyroid medication. Clinical Endocrinology 28 205-214.
43. Weetman AP 1994 The immunomodulatory effects of antithyroid drugs. Thyroid 4 145-146.
44. Weetman AP & McGregor AM 1994 Autoimmune thyroid disease: further developments in our understanding. Endocrine Reviews 15 788-830.
45. Weetman AP, Tandon N & Morgan BP 1992 Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 340 633-636.
46. Yokota A, Kikutani H, Tanaka T, Sato R, Barsumian EL, Suemura M & Kishimoto T 1988 Two species of human Fcε receptor II (FcεRII/CID23): tissue-specific and IL-4-specitic regulation of gene expression. cell 55 611-618.